Stock
Ticker
First
Article
Original
Price
Price
Today
RCPT Nov 17 106.55 Check
URRE Nov 13 2.49 Check
PHMD Oct 29 4.16 Check
IBIO Oct 23 1.77 Check
VIMC Oct 23 9.64 Check
SZYM Oct 16 6.96 Check
AXDX Oct 14 27.38 Check
GLUU Oct 7 5.12 Check
MILL Sept 19 4.96 Check
DGLY Sept 16 20.65 Check
MNDL Aug 26 5.35 Check
FCEL Aug 20 2.76 Check
SYMX Aug 7 1.20 Check
ADES July 11 22.70 Check
TTGT June 19 8.19 Check
ANY.V May 28 9.42 Check
CYBX Apr 16 62.24 Check
OPTT Apr 4 4.19 Check
MDXG Mar 21 7.01 Check
AMRS Mar 7 4.85 Check
UNIS Feb 27 4.65 Check
PHMD Oct 17 15.49 Check
TXMD Feb 14 6.36 Check
SGMO Sept 19 11.21 Check
ZEN.V Sept 9 3.78 Check
XONE Aug 28 71.90 Check
TEAR Aug 1 14.40 Check
CNDO July 15 8.65 Check
RVLT July 2 4.03 Check
LOTE May 5 10.00 Check
LULU April 18 71.34 Check
PSSI Oct 3 23.00 Check
TNGO Aug 28 19.55 Check
MDVN May 31 $85.01 Check
JIVE May 3 $24.09 Check
SNPK April 3 $1.70 Check
QCOR Jan. 11 $41.54 Check
BRLI Nov. 1 $20.04 Check
PANL Oct. 3 $47.94 Check
GORO Aug. 23 $24.32 Check
MILL July 28 $7.04 Check
CIGX June 30 $4.51 Check
JAMN May 16 $5.17 Check
SWSH May 2 $8.77 Check
LEXG April 26 $4.02 Check
NOG March 21 $28.25 Check
VOG March 21 $5.02 Check
HNHI Feb. 17 $1.46 Check
IBIO Feb. 10 $5.17 Check
COUGF Feb. 1 $3.36 Check
LLEN Jan. 11 $10.27 Check
HHWW Dec. 23 $1.63 Check
CYDE Dec. 2 $3.29 Check
SMED Oct. 14 $5.87 Check
RMCP Sept. 21 $0.69 Check
INET Sept. 13 $10.66 Check
CLKZ Aug. 30 $0.53 Check
LQMT Aug. 19 $0.76 Check
LOCM Aug. 4 $6.12 Check
ESPH June 25 $1.49 Check
APOL June 15 $47.60 Check
BPI June 15 $19.63 Check
SILA May 27 $1.14 Check
FLPC May 27 $0.97 Check
AMEL May 27 $1.05 Check
STP May 17 $10.62 Check
BGBR April 26 $1.21 Check
NNLX April 16 $1.10 Check
CHTL April 9 $0.74 Check
AMLM March 25 $1.02 Check
LTUM March 25 $1.25 Check
TRGL March 11 $9.56 Check
TSHO Feb 24 $1.16 Check
CSKI Feb 19 $18.30 Check
GXDX Feb 15 $31.69 Check
JYHW Jan 19 $1.83 Check
AENY Jan 19 $4.51 Check
CLRH Dec 08 $1.35 Check
NXTH Dec 08 $2.28 Check
IMGG Nov 22 $1.39 Check
MEVT Nov 16 $0.35 Check
AWSL Nov 16 $3.29 Check
FRPT Oct 13 $5.84 Check
AEHI Oct. 4 $0.87 Check
URRE Nov 13 2.49 Check

The best new website for learning about penny-stock scams.

Melissa Davis, senior editor of The Street Sweeper, poses with celebrity stock picker Jim Cramer after a recent taping of his "Mad Money" television show. Davis worked as an investigative reporter for TheStreet.com, where Cramer serves as chairman, before assuming her current role at The Street Sweeper.

Blue Nile: Breaking Hearts And Share Value

by Sonya Colberg, Senior Investigative Reporter, 11/20/2014 12:25:19 PM

Diamond seller, Blue Nile (NILE), is in the business of turning romance into cold, hard cash.

As if that isn’t tough enough, the Seattle, Wash. diamond and jewelry retailer is selling online. While the company’s courtship of customers is getting tougher, recent creative hype has blinded investors into buying into the dream and pushing the market cap to a stunning $400 million.

But this love story is doomed. Here are some highlights on why TheStreetSweeper believes the diamond company will quickly lose its sparkle once again:

*Diamonds are a girl’s best friend: Cheap won’t cut it.

NILE’s engagement business is at risk partially because a woman may feel a slight wave of disappointment when Prince Charming shows up with a diamond – and it’s from a Wal-Mart-esque online store.

NILE execs admitted during a summertime William Blair stock conference, in fact, that the biggest problem is getting men to buy engagement rings online because there’s “a trust component and then there’s a relationship component.”

CEO Harvey Kanter added, “I think that that -- the reason why growth rates haven't been sustainably high has been that we still have to get a lot of the market to understand that.”

*NILE’s recent “test:” Weakening business model.

Mr. Kanter said NILE is now “testing” a brick-and-mortar store in Rhode Island and in Seattle. This appears to be a test of the idea that customers may consider buying engagement diamonds online less satisfying and riskier than seeing and touching them in a store first.

Keep in mind that the reason NILE can sell jewelry cheaper is because, as an online company, it has been able to avoid the costs of physical buildings, utilities and sales people of traditional jewelry stores. And now it’s trying to compete in brick-and-mortar with thousands of established jewelry stores.



Receptos: A Bloated Highflier Dumped by Insiders Nervous about the Truth?

by Melissa Davis, 11/17/2014 10:25:12 AM

Receptos (Nasdaq: RCPT) looks even luckier than usual right now. The bleeding biotechnology firm has racked up such mind-blowing gains over the past few weeks, in fact, that even its own executives – who just dumped more than $35 million worth of the company’s highflying stock – must wonder how long its good fortune can actually last.

With its stock price recently exploding into the triple digits, making the company worth a staggering $2.9 billion years before it even hopes to seek approval of its very first drug, Receptos arguably looks priced beyond perfection at this point.

For starters, Receptos now owes more than a third of its lofty valuation to a Phase II study that barely even managed to achieve its primary goal. When Receptos issued a positive update about that ongoing trial a few weeks ago – sparking a wild celebration that expanded its market value by almost $1 billion in a single day – the firm actually provided enough underlying data to reveal that a tiny handful of patients happened to narrowly swing the results in its own favor.

Just pull out that announcement and grab your calculator. Once you complete a few simple equations, you’re bound to arrive at that striking conclusion yourself.

Start with the 199 patients that Receptos enrolled in its “Touchstone” trial, a Phase II study designed to test its leading drug candidate RPC1063 as a possible treatment for ulcerative colitis (UC), and then divide those subjects into three different groups: one for patients who received a “high” 1 milligram dose of the drug; one for patients who received a “low” 0.5 milligram dose of the same medication; and one for those who received an inactive placebo. Assume that Receptos made sure that its researchers distributed those subjects as evenly as possible, with 66.3 patients assigned to each arm of the trial. Now, you can estimate just how many patients actually recovered after taking the company’s experimental drug.

Of the patients treated with RPC1063 during the eight-week induction period of that clinical trial, only 16.4% of those who received the high dose and 13.8% of those who received the low dose – or the equivalent of 10.9 and 9.2 patients, respectively – achieved clinical remission to meet the primary endpoint of that ongoing study. Even so, the high-dose group somehow fared well enough to hit the primary endpoint of the study by achieving “statistically significant” positive results. In the second group, however, the recovery rate – lowered by just one or two patients – fell short of reaching that crucial goal.

Talk about a very near miss!

Who knows if RPC1063 really sent those patients into remission, either? After all, at least some of the patients who received nothing but a placebo actually wound up recovering on their own.

Company insiders have already struck it rich regardless. Unwilling to wait for Receptos to determine whether its experimental UC treatment actually works or not, a crowd of senior executives recently jumped at the chance to hit a surefire jackpot instead.

Earlier this week, nearly half-a-dozen members of the senior management team – including the CEOthe chief medical officerthe chief scientific officerthe chief technology officer and the senior vice president of corporate development – took part in a lucrative insider-selling spree that turned all of them into overnight multimillionaires. The biggest winner by far, Receptos CEO Faheed Hasnain walked away with a gigantic $21.9 million windfall that easily exceeded all of the multimillion-dollar fortunes collected by the remaining four executives combined.

JAMN Finally Spills the Beans -- And It's an Ugly Mess

by Janice Shell, 6/2/2011 10:32:51 AM

* Editor's Note: Readers can access links to additional backup documents for this story by clicking here for TheStreetSweeper's original investigative report on this company.

Late Tuesday afternoon, after missing earlier deadlines, Jammin Java (OTC: JAMN.OB) filed a long-awaited annual report packed with enough eye-opening news to keep investors up all night. That mandatory filing, unaccompanied with a cheerful press release heralding its arrival, served as a painful wake-up call to shareholders already burned by a rapid plunge in the company’s stock price.

To be sure, the 10-K offered investors little reason to sing. For starters, the filing reveals, this once-hot “coffee company” sells no coffee of its own at all. JAMN relies on a supplier based in frigid Canada – far away from the tropical Jamaican home of its co-founder Rohan Marley – to provide the company with an actual product to sell to its customers instead.

Back in April of 2010, JAMN inked a “supply and toll agreement” with Canterbury Coffee of British Columbia that gave it access to some brew. According to that agreement, JAMN relies on Canterbury to fulfill every role – save a minor one – normally satisfied by a firm that classifies itself as a coffee company. Canterbury purchases the coffee beans. It roasts them. And it then packages them in bags supplied by JAMN – the company’s only real product – for sale to the public.

JAMN signed this deal more than a year ago, right before Shane Whittle – a notorious Vancouver stock promoter – officially resigned as CEO of the company. But the company never mentioned that agreement, seemingly material enough to warrant at least a quiet 8-K report, in a single regulatory filing until now.   

Jammin Java (JAMN): Hot Stock ... Bitter Aftertaste?

by Janice Shell, 6/2/2011 10:30:25 AM

It’s time to wake up and smell the coffee! That’s exactly what Jammin Java (OTC: JAMN.OB), a heavily promotedcoffee company, and – for very different reasons – TheStreetSweeper would like investors to do.

Since the beginning of the year, JAMN has miraculously risen from the ashes of the “Grey Market” graveyard to become one of the liveliest – and richest – stocks in the entire microcap arena. JAMN has seen its stock shoot straight toward heaven, soaring from 55 cents to peak above $6 a share on massive daily volume, with its market value nowtopping $355 million despite the company’s limited resources and operating history. (As covered in more detail below, two of the Internet tout sheets pushing JAMN the hardest effectively vanished -- disabled by their Internet servers -- on the day the stock’s trading volume exploded past 20 million shares.) 

JAMN stands out for its powerful connections, the first loudly celebrated by the company and the second – involving a notorious stock promoter – carefully hidden from view.


 

CCME: Few Signs of Life at 'Healthy' Chinese Firm

by Roddy Boyd, 3/23/2011 9:30:34 AM

* Editor's Note: This story has been republished with permission from The Financial Investigator. To access the original article, complete with links to back-up documents, click here.

In the maze of thronged and narrow streets that makes up Fujian province’s capital city of Fuzhou, a deft driver, if he’s willing–as all Chinese drivers apparently are–to nearly kill or injure vast numbers of his countrymen can take you to the foot of Dongjie street. There was little reason to be there save for its having the headquarters of a company called China MediaExpress Holdings (Nasdaq: CCME), an enterprise that seems to be able to weather allegations about its business that would have forced the share price collapse of a company five times its size. The attention of bulls and bears is not misplaced: In a mere four years as a public company, it has apparently come to dominate the ad placement market for leading multinational consumer products companies on a network of what it claims is more than 27,000 buses on Chinese airport and intercity routes.

Also, and this cannot be understated, hanging out on a sidewalk in Fujian–the sidewalks double as parking spots when the streets, which appeared to have been designed in the Han Dynasty, fill up–was not a viable option. There was also the matter of the world-class headache the Financial Investigator was developing from Fuzhou’s diabolical smell, an epic conflation of poor sewage treatment, air pollution and the smell of cabbage that made getting the hell off Dongjie street a matter of vital importance.

The Financial Investigator and his traveling companion for the trip, an American investor with extensive experience in China, decided to head upstairs despite our interview with the CFO having been cancelled at the last minute (with no explanation given.) We thought a quick tour of the offices and meeting a few other executives might open our eyes to a few things.

It did.

Though the language barrier was a little steep with the young receptionist–when we asked for writing paper, she provided Kleenex–we were in short order shown to their conference room and told to wait. It did not escape notice that pride of place in the conference room belonged to a framed certificate of participation from the Fall 2010 Rodman & Renshaw conference, the World Cup for reverse merger companies and the pumpers and touts who peddle them.

Eventually chief operating officer James Yu came down and after spending 30 minutes trying to understand who we were, concluded that giving us a tour wouldn’t hurt. Soon enough, his colleague, Vinne Ye–the chairman’s assistant–came out and took us around.

It was most eye-opening.

more...

Signup For Alerts
When new stories are published
Email:  

The Street Sweeper Is Not A Fan of Glu Mobile Inc.'s Kim Kardashian Game (GLUU):

Read the Article
Read the GLUU Story

Glu Mobile Falls as Kardashian Game Drops in Rankings (GLUU):

Read the Article
Read the GLUU Story

CNBC on TheStreetSweeper's coverage of Gold Resource Corporation: (GORO):
"Herb Greenberg comments on Gold Resource Corporation"

Watch the Video
Read the GORO Story

CNBC on TheStreetSweeper's coverage of Miller Energy Resources: (MILL):
"Melissa Davis at TheStreetSweeper … wrote a piece on this thing that obviously scared investors a little bit … It was an excellent reporting job (and) has moved the stock dramatically."

Watch the Video
Read the MILL Story

Herb Greenberg's View (NOG):
"There are questions about related parties … Sometimes companies just don't pass that 'sniff test.'"

Watch the Video
Read the NOG Story

Cramer's View (SWSH): "I wouldn't touch Swisher with a 10-foot PLUNGER!"
Watch the Video
Read the SWSH Story

Cramer's View (NOG): "I clearly have been jarred by the accounting issues and feel like, right now, the momentum has left this stock."
Watch the Video
Read the NOG Story

New Article Alert! Sign up to get notified of new articles.  Click Here. Subscribe
     
| More

Investors must be properly armed in order to protect themselves against the dangers of Wall Street. To help out, The Street Sweeper has mined the Internet for the most powerful weapons available to investors researching publicly traded companies. In our “Loaded Weapons” section, you’ll find direct links to corporate documents filed with the SEC, conference call transcripts published by Seeking Alpha, insider stock sales tracked by Insider-Monitor.com and popular investment tools offered by Yahoo! Finance. You can also identify the promoters behind current penny stock campaigns – and the compensation they are receiving – by connecting to StockPromoters.com. You can link to other websites that are conducting topnotch stock investigations as well. Click here now.

When investors begin their homework on small-cap companies - particularly on penny stocks - they should probably start with an important history lesson. Specifically, they should conduct background checks on their stockbrokers and the companies those brokers are touting.
 
The Street Sweeper has designed a cheat sheet of sorts to help out with this research. Our “Rap Sheet” section links to a free tool (sponsored by FINRA) that allows ordinary investors to review the backgrounds of individual stockbrokers and their brokerage firms. The section also links to whistleblower cases and class-action lawsuits targeting publicly traded companies. It provides access to recent news of SEC enforcement actions and FBI white-collar crime investigations as well.
click here now.